BCRX Q4 2021 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$47M+1074.3% YoY

Gross Profit

$47M99.1% margin

Operating Income

-$52M-110.6% margin

Net Income

-$18M-37.7% margin

EPS (Diluted)

$-0.10

QoQ Revenue Growth

+15.0%

Cash Flow

Operating Cash Flow

-$32M

Free Cash Flow

-$34M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$588M

Total Liabilities

$695M

Stockholders' Equity

-$107M

Cash & Equivalents

$504M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$47M	$4M	+1074.3%
Gross Profit	$47M	$4M	+1087.8%
Operating Income	-$52M	-$52M	+0.4%
Net Income	-$18M	-$60M	+70.6%

Revenue Segments

Collaborative and Other Research and Development

$903,000100%